Patients with weight loss who take Zepbound forced to change Wogovy after coverage drop
NEWNow you can listen to News articles!
Some patients who take GLP-1 medications to lose weight have been forced to change to a different medication due to a change in insurance coverage, and are not happy with that.
As of July 1, CVS Caremark, one of the largest pharmacy benefits managers in the US, discovered Zepbound (Tirzepatide) of his list of preferred medications, replacing it with Wogovy (Semaglutida).
Eli Lilly makes Zepbound, along with his counterpart of diabetes, Mounjaro, is made by Eli Lilly, while Wegovy is produced by Novo Nordisk, which also does Ozempic.
CVS Caremark Dropping popular drug coverage
CVS Caremark blamed the growing costs for change. In a June 27 statement on its website, the company said that “drug manufacturers are the only ones responsible for establishing the price of medicines and have valued these medications at a high cost, which makes it difficult for many people to access them.”
In an effort to “reduce the prices of pocket medications,” CVS CareMARK said it associated with Novo Nordisk to “significantly increase Wogovy access to our members at a more affordable price.”
Some patients who take GLP-1 medications to lose weight have been forced to change to a different medication due to a change in insurance coverage. (Istock)
“On July 1, 2025, we will take a form action to prefer Wagovy and eliminate the Zepbound,” the statement continued. “We trust that our decision to prefer Wagovy in our commercial template forms will allow broader and affordable coverage for weight control medications, while preserving clinical integrity.”
Dr. Tro Kalayjian, a doctor certified by the Board that practices internal and obesity medicine based in New York, said that the lack of choice of the patient always negatively affects patients.
The study reveals a main cause of obesity, and it is not a lack of exercise
“Some people do not tolerate certain medications, and being forced to change a new drug presents a clear way to stop progress,” Digital told News. “Forced change interrupts the continuity of attention.”
“The change of drugs is not always perfect; the dosage must often return to the title and the side effects can resurface.”
Wegovy is an injectable prescription weight loss medicine made by the Danish company Novo Nordisk. (Michael Siluk/UCG/Universal Image Group through Getty Images)
Many patients who received Caremark letters about change have led social networks to express their concerns.
“I was approved for Zepbound two months ago … I’ve only been in it for two months and I have already dropped 25.8 pounds,” a Reddit user wrote. “I have increased my dose twice since I am now in the third month, and I have had little or no side effect. It has worked very well for me, I am really nervous for having to change medicines.”
The popular weight of weight loss medications shows a new promising power against weakening migraines
Another user wrote: “CVS has just sent a letter that indicated that it was no longer covered and could make the transition to Wogovy. However, I tried Wagovy before Zepbound and gave me sick profusely.
“He has been working very well for me, I’m really nervous for having to change medicines.”
CVS Caremark declared in his announcement that patients who previously tested Wogovy and
The “serious or intolerable side effects” experienced “or” did not achieve enough weight loss “can request an” form of form “to be covered for a different weight loss medication.
“You or your supplier can initiate an exception application, which allows a review of medical need for a case -by -case basis to determine if the coverage for alternative therapy is appropriate based on your clinical circumstances,” said the company.
Eli Lilly performs Zepbound, along with his counterpart of diabetes, Mounjaro, is made based in Indianapolis. (Istock)
Patients can choose to buy Zepbound directly from Eli Lilly, Kalayjian said, but the medicine is expensive, which costs approximately $ 300- $ 500 per month.
“Unfortunately, people are so desperate that they are buying versions of the degree of research of Tiktok medications and social networks,” he warned.
Click here to get the News application
Kalayjian said Zepbound is “slightly more effective” than Wagovy, since it has an additional mechanism, but both drugs are “very similar” in their weight loss results.
“There is a little less nausea and vomiting with Zepbound,” he added.
A recent study found that the tirzepatido achieved greater weight loss than the semaglutida, with the participants who spilled around 50 pounds (20.2% of their body weight). (Istock)
In a recent 72 -week clinical trial published in the New England Journal of Medicine, researchers compared the safety and efficacy of the tirzepatido (Zepbound) and the semaglutida (Wegovy).
Click here to register in our health newsletter
The study found that the tirzepatide achieved Greater weight losswith the participants who spilled around 50 pounds (20.2% of their body weight).
The group that took Semaglutida lost an average of 33 pounds or 13.7% of its basal weight, according to a press release that summarizes the study result.
“The change of drugs is not always perfect; the dosage must often return to the title and the side effects can resurface,” said an expert. (Istock)
In general, 32% of people who take Tirzepaturo lost at least 25% of their body weight; Semaglutidas users lost around 16%.
Tirzepatide users also reported a “greater reduction in the circumference of the waist” than those of the semaglutida.
For more health articles, visit www.Newsnews.com/health
The informed side effects were very similar for the two drugs, with 44% of the people who experienced nausea and 25% with abdominal pain.
News Digital contacted Eli Lilly and Novo Nordisk to comment.
Melissa Rudy is a senior health editor and a member of the lifestyle in News Digital. The advice of history can be sent to melissa.rudy@News.com.